Prescription Drug Price Relief Act of 2019
Latest action · Jan 25, 2019 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 10, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Prescription Drug Price Relief Act of 2019
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.
Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.
The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
Cosponsors 22
Members who signed on, in the order they did. Signatures ran from Jan 10, 2019 to Apr 30, 2019; 14 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NY | Alexandria Ocasio-Cortez | Original | Jan 10, 2019 |
| D-MA | Ayanna Pressley | Original | Jan 10, 2019 |
| D-CA | Barbara Lee | Original | Jan 10, 2019 |
| D-MD | Elijah E. Cummings | Original | Jan 10, 2019 |
| D-MN | Ilhan Omar | Original | Jan 10, 2019 |
| D-IL | Janice D. Schakowsky | Original | Jan 10, 2019 |
| D-CO | Joe Neguse | Original | Jan 10, 2019 |
| D-WI | Mark Pocan | Original | Jan 10, 2019 |
| D-OR | Peter A. DeFazio | Original | Jan 10, 2019 |
| D-VT | Peter Welch | Original | Jan 10, 2019 |
| D-WA | Pramila Jayapal | Original | Jan 10, 2019 |
| D-MI | Rashida Tlaib | Original | Jan 10, 2019 |
| D-CT | Rosa L. DeLauro | Original | Jan 10, 2019 |
| D-HI | Tulsi Gabbard | Original | Jan 10, 2019 |
| D-FL | Debbie Mucarsel-Powell | Jan 15, 2019 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 10, 2019 |
| Health Subcommittee | Referred Jan 25, 2019 | |
| House | Judiciary Committee | Referred Jan 10, 2019 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred Jan 10, 2019 |
Actions 4
Everything that happened, newest first.
- Jan 25, 2019Referred to the Subcommittee on Health.
- Jan 10, 2019Introduced in House
- Jan 10, 2019Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jan 10, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 5, January 10, 2019, page H464.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 102 | Prescription Drug Price Relief Act of 2019 | Identical bill | Jan 10, 2019 |
| HR 2148 | Prescription Drug Price Relief Act of 2021 | Reintroduced Bill | Oct 19, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
- Short Title(s) as Introduced
- Prescription Drug Price Relief Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative remedies
- Asia
- Business records
- Canada
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Europe
- France
- Germany
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health information and medical records
- Inflation and prices
- Intellectual property
- Japan
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Medical research
- Prescription drugs
- Research and development
- United Kingdom
Text 1
Each version as it was printed, newest first.
- Jan 10, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.